Format

Send to

Choose Destination
Cancer Cell. 2010 Nov 16;18(5):448-58. doi: 10.1016/j.ccr.2010.10.020.

Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells.

Author information

1
Cell and Molecular Biology Program, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.

Abstract

Mutational activation of KRas is the first and most frequently detected genetic lesion in pancreatic ductal adenocarcinoma (PDAC). However, the precise role of oncogenic KRas in the pathogenesis of PDAC is not fully understood. Here, we report that the endogenous expression of oncogenic KRas suppresses premature senescence in primary pancreatic duct epithelial cells (PDEC). Oncogenic KRas-mediated senescence bypass is conferred by the upregulation of the basic helix-loop-helix transcription factor Twist that in turn abrogates p16(INK4A) induction. Moreover, the KRas-Twist-p16(INK4A) senescence bypass pathway is employed in vivo to prevent inflammation-associated senescence of pancreatic ductal epithelium. Our findings indicate that oncogenic KRas could contribute to PDAC initiation by protecting cells from entering a state of permanent growth arrest.

PMID:
21075310
PMCID:
PMC3397918
DOI:
10.1016/j.ccr.2010.10.020
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center